Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 6, 2008, Pages 558-565

  DiSantostefano, Rachael L ^a   Davis, Kourtney J ^a   Yancey, Steve ^a   Crim, Courtney ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; SALMETEROL;

ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; ECOLOGY; HOSPITALIZATION; HUMAN; MORTALITY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

EID: 45149085200     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60048-8     Document Type: Article

References (37)

1. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-1037.
2. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26. Erratum in: Chest. 2006;129:1393.
3. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by Prescription-Event Monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol. 1996;49:247-250.
4. Lanes SF, Lanza L, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med. 1998;158:857-861.
5. Meier CR, Jick H. Drug use and pulmonary death rates in increasing symptomatic asthma patients in the UK. Thorax. 1997;52:612-617.
6. Williams C, Crossland L, Finnerty J, et al. A case-control study of salmeterol and near-fatal attacks of asthma. Thorax. 1998;53:7-13.
7. Lanes SF, Garcia Rodriquez LA, Hueta C. Respiratory medications and risk of asthma death. Thorax. 2002;57:683-686.
8. 2 agonists. Thorax. 1998;53:558-562.
9. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ. 2005;330:117-124.
10. Beasley R, Pearce N, Crane J, Burgess C. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol. 1999;104(2 pt 2):S18-S30.
11. Verispan Vector One National [database]. Yardley, PA: Verispan Inc; 2005.
12. American Lung Association Epidemiology & Statistics Unit Research and Program Services. Trends in Asthma Morbidity and Mortality. July 2006. www.lungusa.org. Accessed September 14, 2006.
13. Kozak LJ, Lees KA, DeFrances CJ. National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2006; 160:1-206. www.cdc.gov. Accessed June 29, 2006.
14. Miniño AM, Heron MP, Smith BL. Deaths: preliminary data for 2004.Natl Vital Stat Rep. 2006;54:1-49. www.cdc.gov. Accessed June 29, 2006.
15. Mannino DM, Homa DM, Pertowski CA, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma - United States, 1960-1999. MMWR CDC Survill Summ. 2002;51(SS01):1-13. www.cdc.gov/mmwr/. Accessed on June 1, 2007.
16. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. et al. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep. 2001;49:1-32.
17. Guite HF, Dundas R, Burney PG. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax. 1999;54:301-307.
18. Tough SC, Green FH, Paul JE, Wigle DT, Butt JC. Sudden death from asthma in 108 children and young adults. J Asthma. 1996;33:179-188.
19. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma. 1998;35:657-665.
20. Jalaludin BB, Smith MA, Chey T, Orr NJ, Smith WT, Leeder SR. Risk factors for asthma deaths: a population-based, case-control study. Aust N Z J Public Health. 1999;23:595-600.
21. Sturdy PM, Butland BK, Anderson HR, et al; National Asthma Campaign Mortality and Severe Morbidity Group. Deaths certified as asthma and use of medical services: a national case-control study. Thorax. 2005;60:909-915.
22. Lane WG, Newman D, Edwards M, Blaisdell C. Disparities in the circumstances of asthma deaths in Maryland. J Asthma. 2006;43:777-782.
23. Gupta RS, Carrion-Carire V, Weiss KB. The widening black/white gap in asthma hospitalizations and mortality. J Allergy Clin Immunol. 2006;117:351-358.
24. Lang DM, Polansky M. Patterns of asthma mortality in Philadelphia from 1969 to 1991. N Engl J Med. 1994;331:1542-1546.
25. Castro M, Schectman KB, Halstead J, Bloomberg G. Risk factors for asthma morbidity and mortality in a large metropolitan city. J Asthma. 2001;38:625-635.
26. Bucknall CE, Slack R, Godley CC, Mackay TW, Wright SC. Scottish confidential inquiry into asthma deaths (SCIAD), 1994. Thorax. 1999;54:978-984.
27. Hessel PA, Mitchell I, Tough S, et al; Prairie Provinces Asthma Study Group. Risk factors for death from asthma. Ann Allergy Asthma Immunol. 1999;83:362-368.
28. Sturdy PM, Victor CR, Anderson HR, et al, of the Mortality and Severe Morbidity Working Group for the National Asthma Task Force. Psychological, social and health behavior risk factors for deaths certified as asthma; a national case-control study. Thorax. 2002;57:1034-1039.
29. Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer H, Forbes AB, McNeil JJ, Walters EH, and the Victorian Asthma Mortality Study Group. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med. 2001;163:12-18.
30. Barton CA, McKenzie DP, Walters EH, Abramson MJ; The Victorian Asthma Mortality Study Group. Interactions between psychosocial problems and management of asthma: who is at risk of dying? J Asthma. 2005 May;42(4):249-56.
31. Wechsler ME, Lehman E, Lazarus SC et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519-526.
32. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118:809-816.
33. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17:189-196.
34. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001;107:937-944.
35. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245-251.
36. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med. 2005;99:1263-1267.
37. O'Connor RD, Rosenzweig JR, Stanford RH, Gilmore AS, Ryskina KL, Legorreta AP, Stempel DA. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol. 2005;95:535-540.